Applied Cardio-Oncology in Hematological Malignancies: A Narrative Review.
Evdokia MandalaKyranna LafaraDimitrios KokkinovasilisIoannis KalafatisVasiliki KoukoulitsaEirini KatodritouChristos LafarasPublished in: Life (Basel, Switzerland) (2024)
Applied cardio-oncology in hematological malignancies refers to the integration of cardiovascular care and management for patients with blood cancer, particularly leukemia, lymphoma, and multiple myeloma. Hematological cancer therapy-related cardiotoxicity deals with the most common cardiovascular complications of conventional chemotherapy, targeted therapy, immunotherapy, chimeric antigen receptor T (CAR-T) cell and tumor-infiltrating lymphocyte therapies, bispecific antibodies, and hematopoietic stem cell transplantation. This narrative review focuses on hematological cancer-therapy-related cardiotoxicity's definition, risk stratification, multimodality imaging, and use of cardiac biomarkers to detect clinical and/or subclinical myocardial dysfunction and electrical instability. Moreover, the most common cardiotoxic profiles of the main drugs and/or therapeutic interventions in patients with hematological malignancies are described thoroughly.
Keyphrases
- cancer therapy
- palliative care
- drug delivery
- multiple myeloma
- acute myeloid leukemia
- left ventricular
- healthcare
- high resolution
- bone marrow
- papillary thyroid
- diffuse large b cell lymphoma
- risk factors
- quality improvement
- locally advanced
- young adults
- mass spectrometry
- rectal cancer
- atrial fibrillation
- pain management
- lymph node metastasis